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Abstract
Background: Symptomatic iron deficiency (ID) is a disorder affecting 10–20% of menstruating women. ID is
diagnosed by measuring serum ferritin, a protein helping to store iron in the body. A deeper understanding of the
association between ID and its societal and economic burden is relevant for patients, physicians, health care
decision makers.
Methods: An online household survey was carried out among Swiss women aged 18–50 years suffering from
debilitating symptoms due to ID. The data was population-weighted for age and region. The costs of misdiagnosis
and the ID-related economic burden (i.e. days of sick leave) from productivity losses on the labor market were
determined and extrapolated to the Swiss population. Furthermore, the patient burden was assessed based on
quality of life daily measurements.
Results: The total sample included 1010 women who received an ID diagnosis with a blood test in the last 2 years
(mean age: 33.5 years). Most named symptoms were “being tired or exhausted” (96.4%) and reduced physical
energy level (41.0%). In total, 354 (35.0% of the total sample) patients received an initial diagnosis other than ID. Of
those, 46.8% were treated prior to the ID diagnosis with a pharmacological medical therapy or psychotherapy.
Extrapolating these numbers to the Swiss female population aged 18–50 years, the direct medical costs would be
CHF 78 million (assuming an annual ID incidence of ID diagnosis of 9.5%). On average, 28.5% of participants in the
work-force had to take sick leave due to ID symptoms within a period of 2 years (mean: 5.2 days, i.e. 2.6 days/year).
The estimated annual indirect costs in Switzerland would be CHF 33 million (human capital approach) or CHF 26
million (friction cost method), respectively. Being exhausted and impaired concentration appear to be the most
important factors negatively impacting daily living and hence quality of life.
Conclusion: The societal and economic burden among women due to debilitating symptoms of ID in Switzerland
is substantial. Timely, correct diagnosis and treatment of ID may contribute to reducing this burden. Further studies
are needed in this area to validate our results.
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Background
Nearly one-third of the non-pregnant women worldwide
are affected by anemia, of which iron deficiency (ID) is
the primary cause [1, 2]. Symptomatic ID is a nutrient-
related disorder which is significantly prevalent in both
developing and industrialized countries, affecting about
10–20% of menstruating women [3–5]. In addition to
menstrual blood loss, common causes of ID in adults
include inadequate dietary intake, chronic blood loss,
times of increased need (i.e. pregnancy), vigorous exer-
cise and other underlining diseases [6, 7]. Also, an
inability to absorb iron may be play a role [8]. ID can be
diagnosed with measuring the serum ferritin, which is a
protein that helps to store iron in the body [9]. Treat-
ment for ID includes adding iron-rich foods to the diet
and taking iron therapies [5].
Iron deficiency has an impact on the physical perform-
ance, work productivity and cognitive function of affected
individuals [10]. Beside this, intravenous iron therapy (IV
iron) is controversially discussed in Switzerland in clinical
journals, among health insurers and in the press. In 2014,
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the Swiss Medical Board (SMB) has conducted a Health
Technology Assessment (HTA) and came to the conclu-
sion that the administration of IV iron seems to be
reasonable, especially in severe ID patients [11].
A deeper understanding of the association between ID,
quality of life and its societal and economic burden is
important for patients, physicians and health care
decision makers.
The main objective of the present study was to assess
the economic and societal burden of non-pregnant,
female ID patients aged 18–50 years in Switzerland. Dir-
ect costs for a delayed or incorrect diagnosis or a sub-
optimal therapy (i.e. patients diagnosed with other
diagnoses before the diagnosis of ID was confirmed)
were determined. Furthermore, the indirect costs were
quantified for sick leaves of working women due to
debilitating symptoms of ID. Patient burden was quanti-
fied in terms of presence of symptoms, quality of life
and energy level before any ID therapy has started.
Methods
Study design
A population based cross-sectional survey was carried
out among Swiss females aged 18–50 years (Table 1).
The survey was administered during a quantitative
15-min online survey conducted as part of consumer
panels in April 2016. Pre-menopausal women aged 18–
50 years suffering from ID were included according to
specific inclusion criteria. The targeted sample size was
1000 patients.
Within the study sample, there was a slight overrepre-
sentation of 30–39 year old women (28.4%) and an
underrepresentation of 18–29 year olds (39.7%; German-
speaking and French-speaking) and 40–50 years olds
(31.9%; French-speaking), respectively. In Switzerland,
The sample was population-weighted according to age
and region to represent the Swiss female population
between 18 to 50 years.
The questionnaire included screening questions to
identify women who were diagnosed with ID within the
last 2 years. Eligible women were provided with a ques-
tionnaire on ID symptoms, number of consultations for
ID symptoms, the specialization of the physician who
diagnosed ID, and how diagnosis was made. It was
expected that patients might have been diagnosed with
other diseases before they received their ID diagnosis.
Considering typical symptoms of ID, patients were asked
if they had been diagnosed with depression, burnout,
anxiety state, chronic fatigue or others conditions, and
whether this lead to treatment with a medical therapy or
psychotherapy. Patient burden was assessed with ques-
tions regarding the impact on daily living and the
subjective energy-level. Related to the burden, the
number of unproductive days at work and the number
of missed working-days were recorded for women in the
work-force. Demographic information was collected
upfront as part of the consumer panel.
The consumer panel consists of more than 130,000 ac-
tive, recruited panelists between 15 to 74 year-old from
Table 1 Patient characteristics (weighted, rounding errors may
occur)
Variable Total
Net size (N) 1010
Age (Mean in years; 95% CI); Range (in years) 33.5 (32.9; 34.1); 18–50
18–28 years (N, %) 322 (31.9)
29–39 years (N, %) 305 (30.2)
40–50 years (N, %) 383 (37.9)
Region (N; %)
German speaking 767; 75.9%
French-speaking 243; 24.1%
Civil status (N; %)
Unmarried 507; 50.2%
Married 403; 39.9%
Widowed 10; 1.0%
Divorced 78; 7.7%
Work time (N; %)
Working min. 80% 557 (55.2%)
Part-time (less than 80%) 417 (41.3%)
Not working (N; %) 36 (3.5%)
• Studying • 16; 1.6%
• Housewife • 14; 1.4%
• Unemployed • 3; 0.3%
• Other • 3; 0.3%
Swiss Nationality (N; %) 934 (92.4)
Size of household (N; %)
Mean, median (persons) 3.21, 3.0
1 Person 118; 11.7%
2 Persons 174; 17.2%
3 Persons 241; 23.8%
4 Persons 330; 32.8%
5 Persons and more 146; 14.4%
Income level per month (N; %)
≤ CHF 4000 88; 8.7%
CHF 4001 – 6000 165; 16.4%
CHF 6001 – 8000 171; 16.9%
CHF 8001 – 10,000 174; 17.2%
CHF 10,001 – 15,000 106; 10.4%
> 15,000 58; 5.7%
Not reported 246; 24.4%
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all three language areas in Switzerland. The panelists are
actively recruited as part of representative, telephone
studies with landline telephone numbers and randomly
generated mobile telephone numbers. The participation
in the panel is voluntary, non-binding and anonymously.
At the beginning of the survey, participants, consent to
take part is explicitly asked. No specific ethical approval
was required for this type of research, as no identifiers
were collected. The survey among consumer panels was
conducted in line with the Swiss law of data protection
and the national and international codes on market and
social research guidelines which also include ethical
principles [12–16].
Statistics
Baseline characteristics were summarized as numbers
and percentages, means, medians for categorical, nor-
mally distributed and non-normally distributed continu-
ous data, respectively.
Discrete numeric/ continuous variables were analyzed
with a t-test (for non-skewed data) or a nonparametric
test (e.g. Mann-Whitney U test for skewed data). Bivari-
ate associations of categorical variables were assessed
with the chi-squared test.
Associations between energy level and present mis-
diagnosis or sick leave were assessed by Spearman’s
correlation coefficient (rho). Correlation coefficients
can range from − 1 to + 1 for a perfect negative rela-
tionship and a perfect positive relationship, respect-
ively. A value of 0 indicates no correlation. Spearman
correlation coefficients were regarded as suitable to
indicate probable directions of effects but not to
provide reliable estimates of effect size. Therefore, the
strength of the correlations shown should be inter-
preted with caution.
For all statistical tests, two-sided p-value < 0.05 was
used as the level of statistical significance. Ninety five
percent confidence intervals (95% CIs) are reported as
appropriate.
The data analysis was carried out with SPSS version 22.
Costs of misdiagnoses
To assess the impact of misdiagnosis, the direct costs of
four conditions (depression, burnout, anxiety state,
chronic fatigue) with a possibility for ID-like symptoms
were calculated based on per-patient lump sums for
each disease (Table 2) [17, 18]. The estimates of per pa-
tient costs of mild depression [19], anxiety state [20]
stemmed from a recent study analyzing the costs of
non-communicable diseases in Switzerland (2011) [17].
The per-patient costs for burnout/ stress in Switzerland
was based on an analysis by the Secretariat for Economic
Affairs (SECO) for 2003 [21]. The costs for anxiety state
stemmed from a recently published study from the UK,
given that no data from Switzerland was available [18].
The costs from the Swiss publications were corrected
for the increase of health care costs over time by the
Swiss health insurance index by the Swiss Federal Statis-
tical Office (for the year 2015), given the third-party
payer perspective of the analysis [22]. The costs from
the UK study for anxiety was corrected for the volume
and price (for 2010). The volume correction was based
on the nominal and purchasing power per capita health
care cost expenditures in UK compared to Switzerland
[23]. The price correction compares the prices for a
specific intervention in UK and in Switzerland for a
specific year [23]. The costs were applied to Switzerland
by using a correcting factor for the increase of health
care costs based (Swiss health insurance index) [22, 24].
This approach was already used in another study in
Switzerland [17, 25].
The per-patient costs were only applied to the frac-
tions of misdiagnosed patients with a prescribed medical
or psycho-therapy, as reported in the study sample.
Economic burden of ID (based on lost working days;
indirect costs)
ID-related days of sick leave in the female population in
the workforce were assessed and the resulting societal
burden of the disease was calculated as indirect costs.
The indirect costs of lost working days can e.g. be mea-
sured as productivity losses on the labor market, via the
Table 2 Patients with a misdiagnosis and related therapies
Misdiagnosis Frequency Therapy Fraction with misdiagnosis
and therapy among total
sample
Duration of therapy
(medical/psychotherapy, in weeks)
N; % N; % % Mean 95% CI Min; Max.
Depression 113; 11.2 71; 62.2 7.0 104 67; 140 0; 780
Burnout 53; 5.3 22; 41.0 2.2 27 5; 50 0; 416
Anxiety state 52; 5.2 30; 56.5 2.9 51 14; 88 0; 780
Chronic fatigue 71; 7.1 20; 27.5 1.9 54 10; 117 0; 624
Others 65; 6.5 31; 47.0 3.0 34 1; 71 0; 1560
Total 354; 35.3 174; 46.8 17.0 – – –
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human capital approach [26, 27]. This approach assumes
that patients who are absent from work due to ID-like
symptoms and the respective persons are not available
for paid work and not replaced. Under this approach, in-
direct costs are calculated as the number of lost
working-days due to ID multiplied with the mean salary
for 1 working day. As an alternative to the human cap-
ital approach, the friction cost method has been
proposed. This method assumes that contributions of
new or already employed workers make partially up for
the production losses of the person on sick leave. There-
fore, an 80% elasticity for annual labor time versus labor
productivity is introduced (the results based on the
human capital is multiplied with 0.8) [28, 29].
In Switzerland, a yearly average income of CHF 67,400
(full-time employee) was assumed [30]. Therefore, for
the human-capital approach, an average income of CHF
281 per day was anticipated (by assuming a 8.4 h
working day, full-time position) [30]. The assumed daily
rate corresponded to the opportunity costs of a lost
working day. In order to quantify the indirect costs (by
the human capital approach), the number of lost work-
ing days were multiplied with the daily rate of CHF 281.
Results
Sample characteristics
As illustrated in Fig. 1, out of 5301 invited women, 1010
were eligible and included in the final analyses. The total
of 1010 individuals had an ID diagnosis with a diagnostic
test within the last 2 years, they had specific symptoms
of ID and they were not pregnant, not suffering of a
chronic disease or had no operation in the last 8 weeks.
Patient characteristics are shown in Table 1. The mean
age of the included women was 33.5 years, and only
3.5% reported that they were not working.
In 96.4% of cases, “being tired or exhausted” led to the
decision to consult a medical doctor, followed by
reduced physical energy level (41.0%) and headache
(27.7%). In the mean, it took 28.3 weeks until a medical
doctor was consulted due to the named symptoms
(median: 12 weeks, range: 0 weeks n – 1040 weeks). In
total, 700 (69.3%) of all women mentioned a history of
repeated ID diagnosis (mean number of diagnosis: 3.2;
median: 2.0).
ID diagnosis and costs of misdiagnoses due to similar
symptoms
ID diagnosis
In the mean, patients had to visit a medical doctor for
1.7 times (within a time span of 8.5 weeks) until ID was
diagnosed. Most of the ID diagnoses (77.8%) were
confirmed by general practitioners (GPs) followed by
gynecologists (17.9%) and the hospital (0.9%).
Misdiagnosis (initial diagnosis)
A misdiagnosis was assumed in case of an initial diagno-
sis other than ID, in which case the prescribed treatment
other than iron therapy showed a lack of efficacy and in
which iron therapy improved symptoms. Table 2 shows
the frequency of other diagnoses such as depression,
burnout, anxiety state, chronic fatigue and others. In
total, 354 (35.0% of the total sample) patients received
Fig. 1 Flowchart of patient enrollment
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an initial diagnosis other than ID. Of those, 46.8% were
treated prior to the ID diagnosis with a medical therapy
or psychotherapy (16.9% of the total sample). The mean
duration of the therapy ranged between 34 and 104
weeks.
Comparing patients with a misdiagnosis and without a
misdiagnosis shows a statistically significant difference
regarding the mean number of consultations (3.0 versus
1.3, p-value: < 0.001) and the mean duration of sick leave
(9.6 days versus 2.0 days, p-value: < 0.001). This fact
would also have an impact on the health care costs but
was not incorporated in our analysis.
Costs of misdiagnoses
Based on the numbers of patients with an initial diagno-
sis other than ID and the fraction of patients receiving
treatment for the respective disease, the total cost for all
misdiagnosed patients within our sample population was
determined. The per-patient costs for depression (CHF
5085), burnout (CHF 1424), anxiety state (CHF 1318)
or chronic fatigue (CHF 946) were multiplied with
the number of misdiagnosed patients within our
sample [17, 18]. The total costs of all treated patients
ranged between CHF 18,471 for chronic fatigue and CHF
357,385 for depression (Table 2). This would yield in CHF
110 per patient with ID within our sample population.
The costs for depression were the major driver (80.2%) of
the health care costs in our sample.
In order to estimates costs to the Swiss health care
system (budget impact), the number of potential patients
was identified based on the size of the Swiss female
population aged 18–50 years old (n = 1,867,768 in 2014)
[30]. Based on our sample (1010 women diagnosed with
ID during 2 years, of 5301 screened for eligibility), we
assumed an annual incidence of ID diagnosis of 9.5%
(range for sensitivity analysis, +/− 20%: 7.5–11.5%). This
leads to a population-level estimate of N = 177,438 diag-
nosed cases per year (range: 140,083-214,793) [3–5].
According to our observations, a fraction of 14% would
receive a misdiagnosis and an underlying therapy for
depression, burnout, anxiety state and chronic fatigue
(“others” were not taken into account).It is thus expected
that 19,545 to 29,969 Swiss female patients per year may
be potentially misdiagnosed (Table 3). The direct medical
costs resulting therapies would be CHF 78 million (range:
CHF 62 million and CHF 95 million; Fig. 2).
Economic burden of ID due to symptoms (measured as
absence from work)
Absence from work due to symptoms
Within the sample, 291 (28.8%) women mentioned that
they were not able to comply with their daily business (e.g.
work, studies, household) due to the named symptoms
(mean: 11.8 days; median: 5 days). Within those
participants in the workforce, who mentioned that they
were not able to comply with their daily business (N =
287, 28.7%), they had in the mean 5.2 missed work days
over 2 years (hence 2.6 days within 1 year) (Table 4).
Within this sub-sample, there were also women with zero
missed work days. If only women with ≥1 missed work
days due to ID symptoms were taken into account, the
mean missed work days were 10.8 (n = 138, 14.2% of the
total sample). Among housewives, external help was re-
quired for 1.2 days (mean).
Economic burden of ID (measured as absence from work)
In our sample, 974 participants were either full-or
part-time workers (96.5%). Currently, the fraction of
Swiss female in the workforce is 88.9% among 25 to 54
years old [31]. Hence, in our sample, the proportion of
Swiss women working was slightly higher.
Extrapolating these numbers to the Swiss female
population between 18 and 50 years (n = 1,867,768), we
would assume that 177,438 (range: 140,083 to 214,793)
are potentially suffering from ID each year (based on an
incidence of ID diagnosis of 9.5%, range: 7.5 to 11.5%). If
we only consider women in the work-force, the number
would be 157,742 (range: 124,533 to 190,951). In total,
we would assume that 45,430 (range: 35,866 to 54,994
depending true incidence) patients would take on an
average 2.6 days of sick leave due to debilitating symp-
toms of ID per year, yielding a total of 118,117 (range:
92,251 to 142,984)days per year.
Based on an incidence rate of 9.5% (range: 7.5 to
9.5%), the estimated societal economic burden would be
CHF 33 million (range: CHF 26 million to CHF 40 mil-
lion), if calculated with the human capital approach and
CHF 26 million (range: CHF 21 million to CHF 32 mil-
lion) with the friction cost method, respectively (Fig. 3).
Impact on quality of life
To determine the societal burden, patients were asked to
rank various aspects of their life into five categories and
their energy level (0–100%) before any ID therapy. Being
exhausted and impaired concentration appear to be the
Table 3 Number (N) of potential misdiagnoses in the entire
Swiss female population (aged 18–50 years) depending on iron
deficiency incidence
Incidence of iron deficiency
7.5% 8.5% 9.5% 10.5% 11.5%
Depression 9748 11,048 12,348 13,648 14,947
Burnout 3014 3416 3818 4219 4621
Anxiety state 4075 4618 5162 5705 6248
Chronic fatigue 2708 3069 3430 3791 4152
Total 19,545 22,151 24,757 27,363 29,969
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most important factors impacting daily living negatively
and hence quality of life (Fig. 4).
Associations between energy level (before ID diagno-
sis) and present misdiagnosis or sick leave were assessed
by Spearman’s correlation coefficient. A positive, weak
correlation between patients without misdiagnoses and
mean energy level was shown (rho: 0.14; p-value: <
0.001). Furthermore, the analysis indicates a further, but
weak correlation between duration of sick leave and
lower energy level (rho: − 0.19; p-value: 0.01).
Discussion
Despite its high frequency in non-pregnant women,
symptomatic ID is often misdiagnosed as depression,
burnout, anxiety or chronic fatigue. This often leads to
potentially unnecessary and ineffective treatments, with
consequent delay in disease management, postponed
patient recovery, and increased healthcare expenditures.
Among the 1010 ID patients enrolled in this study,
approximatively one third received an initial diagnosis
other than ID. Assuming a 9.5% annual incidence of ID
diagnosis in Switzerland, we estimate that 24,757 (range
± 20%: 19,545 to 29,969) female patients may initially be
misdiagnosed, causing direct medical costs of CHF 78
million (range: CHF 62 million to CHF 95 million). This
excludes cases which are misdiagnosed but do not get a
correct diagnosis, and thus could not be considered in
our survey. Concerning the overall burden of ID in
terms of absence of work, we estimate that 45,430 work-
ing women in Switzerland take on average 2.6 days of
sick leave due to debilitating symptoms of ID per year,
yielding in 118,117 days per year. The resulting indirect
costs would consequently be CHF 33 million or CHF 27
million using a human capital approach or a friction cost
method. This estimate only covers women who received
an ID diagnosis within two years, the target population
Fig. 2 Extrapolation to the Swiss population depending on ID incidence: Total direct costs (CHF) for misdiagnosis of ID
Table 4 Missed work-days among full, part time and non-working participants
Total sample Persons not able to
comply with work
Persons not able to
comply with work
Number of days not able
to comply with work
Missed
work daysa
Missed
work daysb
Required
external help
N N % Mean days Mean days Mean days Mean days
Full time (≥ 80%) 557 158 28.4 11.52 3.66 6.75
Part time (< 80%) 417 119 28.5 12.39 7.33 18.9
Not working 35 13 37.1 9.18 – – 1.2
Total 1010 291 28.8 11.8 5.2 10.8 1.2
a including those with 0 missed work days
b excluding those with 0 missed work days
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of our survey. This implies an underestimation if one as-
sumes that absences from work are actually independent
of ID diagnosis and treatment, i.e. that undiagnosed pa-
tients also miss work days due to ID related symptoms.
The analysis of the quality of life showed women
suffering from ID often feel exhausted or have concen-
tration problems. Moreover, females receiving a correct,
timely ID diagnosis reported higher mean energy levels,
suggesting that misdiagnoses have a negative impact on
their quality of life.
The results of this study are in line with several works
published in the last decades and addressing the prob-
lems related to nutrition and to ID. Already in 1987,
Arthur et al. suggested that ID is often misunderstood,
Fig. 3 Estimated societal economic burden/ indirect costs of ID patients in Switzerland due to sick leave (HCA: human capital approach; FCM:
friction cost method)
Fig. 4 Factors with an impact on quality of life before ID treatment (frequency, %)
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misdiagnosed and mistreated [32]. Kostopoulou and col-
leagues published a systematic search of the MEDLINE
and EMBASE databases regarding the diagnostic
difficulty and error of iron deficiency in primary care
practice [33]. They suggested that ID is often considered
a simple result of menstruation rather than a potential
disease causing entity. In a cost-benefit analysis the ef-
fects of nutritional programs on ID and ID anemia was
investigated. It has been suggested that medical iron
therapy and fortification of food with iron may have a
great economic impact by increasing the individual
productivity [34].
The present work has several limitations. Firstly, the
analyzed sample was enrolled through an online survey.
Although nowadays most of the pre-menopausal women
aged 18–50 years may easily have access to an online
platform, we cannot exclude a selection bias. Secondly,
as in all consumer panels, there is a certain risk of infor-
mation bias. Despite this, consumer surveys are a very
effective and fast way of generating data regarding a
specific research question. A third limitation is the inclu-
sion of German-speaking and French-speaking women
only. Women speaking Italian and other non-national
languages were excluded mainly due to the fact that the
sample size would have been too small to detect differ-
ences with sufficient precision. This may reduce the
representativeness of the study results for the entire
country, including foreign persons. A fourth limitation is
the assumption that the annual incidence of ID diagnosis
in non-pregnant Swiss women aged 18–50 years is 9.5%
(range: 7.5 to 11.5%), based on a comparison of assessed
and eligible women in our survey. Published incidence
data are lacking. The assumed range of +/− 20% was
chosen to keep the estimate conservative. Recent estima-
tions of the WHO suggested that the prevalence of
women aged 15–49 years with anemia in Switzerland
may range between 9 and 44% [1]. However, prevalence
estimates do not provide a suitable basis for estimating
costs of misdiagnosis and indirect costs (societal
burden), in combination with our survey results.
An additional limitation is related to the calculation of
the costs of misdiagnoses at the national level. It could
be assumed that all patients with ID consulting a med-
ical doctor would be treated. This might lead to an over-
estimation of the costs, since not all patients would wish
or receive a medical treatment. Therefore, we applied in
our analysis only costs to those patients receiving a
therapy in reality, i.e. around 50% of the misdiagnosed
patients. This should have reduced the overestimation,
at least in part.
In addition, we were not able to rule out any con-
founding of co-diagnosis of patients primarily diagnosed
with a disease other than ID. Some patients might suffer
from several diagnoses, e.g. patients diagnosed with
depression might also suffer from ID and vice versa.
Within the survey, a misdiagnosis was clearly defined as
an initial diagnosis with unsuccessful therapies and
where ID therapy was successful, but misunderstanding
cannot be ruled out.
Conclusion
The societal and economic burden of sick leave of
working women due to debilitating symptoms of ID in
Switzerland is substantial. Timely, correct diagnosis and
treatment of ID may contribute to reducing this burden.
Further studies are needed in this area to validate our
results.
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